184 related articles for article (PubMed ID: 35805197)
1. Formation of Lymphoma Hybrid Spheroids and Drug Testing in Real Time with the Use of Fluorescence Optical Tweezers.
Duś-Szachniewicz K; Gdesz-Birula K; Nowosielska E; Ziółkowski P; Drobczyński S
Cells; 2022 Jul; 11(13):. PubMed ID: 35805197
[TBL] [Abstract][Full Text] [Related]
2. Development and Characterization of 3D Hybrid Spheroids for the Investigation of the Crosstalk Between B-Cell Non-Hodgkin Lymphomas and Mesenchymal Stromal Cells.
Duś-Szachniewicz K; Gdesz-Birula K; Rymkiewicz G
Onco Targets Ther; 2022; 15():683-697. PubMed ID: 35747403
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of single lymphoma primary cells and normal B-cells based on their adhesion to mesenchymal stromal cells in optical tweezers.
Duś-Szachniewicz K; Drobczyński S; Woźniak M; Zduniak K; Ostasiewicz K; Ziółkowski P; Korzeniewska AK; Agrawal AK; Kołodziej P; Walaszek K; Bystydzieński Z; Rymkiewicz G
Sci Rep; 2019 Jul; 9(1):9885. PubMed ID: 31285461
[TBL] [Abstract][Full Text] [Related]
4. Physiological Hypoxia (Physioxia) Impairs the Early Adhesion of Single Lymphoma Cell to Marrow Stromal Cell and Extracellular Matrix. Optical Tweezers Study.
Duś-Szachniewicz K; Drobczyński S; Ziółkowski P; Kołodziej P; Walaszek KM; Korzeniewska AK; Agrawal A; Kupczyk P; Woźniak M
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29949925
[TBL] [Abstract][Full Text] [Related]
5. [Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma].
Pérez-Lozano U; Tripp-Villanueva F; Ramírez-Alvarado A; Vela-Ojeda J; Limón-Flores A; Kramis-Cerezo JL
Rev Med Inst Mex Seguro Soc; 2012; 50(4):449-51. PubMed ID: 23234751
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
[TBL] [Abstract][Full Text] [Related]
9. [Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
Hansen PB; Gaarsdal E
Ugeskr Laeger; 2009 Nov; 171(45):3272-5. PubMed ID: 19887056
[TBL] [Abstract][Full Text] [Related]
10. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
Choi HY; Yong CS; Yoo BK
Ann Pharmacother; 2010 Jan; 44(1):117-26. PubMed ID: 20009003
[TBL] [Abstract][Full Text] [Related]
13. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
Devine SM; Flomenberg N; Vesole DH; Liesveld J; Weisdorf D; Badel K; Calandra G; DiPersio JF
J Clin Oncol; 2004 Mar; 22(6):1095-102. PubMed ID: 15020611
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140
[TBL] [Abstract][Full Text] [Related]
15. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
Basak GW; Knopinska-Posluszny W; Matuszak M; Kisiel E; Hawrylecka D; Szmigielska-Kaplon A; Urbaniak-Kujda D; Dybko J; Zielinska P; Dabrowska-Iwanicka A; Werkun J; Rzepecki P; Wroblewska W; Wiktor-Jedrzejczak W
Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660
[TBL] [Abstract][Full Text] [Related]
17. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
Jantunen E; Varmavuo V; Valtola J
Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
[TBL] [Abstract][Full Text] [Related]
19. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating GM
Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
